FMP
PTC Therapeutics, Inc.
PTCT
NASDAQ
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.
54.5 USD
1.74 (3.19%)
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2.76B
1.76B
1.57B
1.39B
1.38B
1.18B
1B
853.43M
727.07M
619.42M
-
-36.34
-10.71
-11.56
-0.61
-14.81
-14.81
-14.81
-14.81
134.53M
19.82M
-133.01M
76.93M
62.37M
17.84M
15.2M
12.95M
11.03M
9.4M
4.87
1.13
-8.47
5.54
4.52
1.52
1.52
1.52
1.52
-33.71M
-36.27M
-27.65M
-23.55M
-23.6M
-19.87M
-16.93M
-14.42M
-12.29M
-10.47M
-1.22
-2.06
-1.76
-1.7
-1.71
-1.69
-1.69
-1.69
-1.69
100.82M
-16.45M
-160.66M
53.38M
38.77M
-2.03M
-1.73M
-1.47M
-1.26M
-1.07M
1.91
32.56M
10.51
10.51
366.79M
62.19M
428.98M
85.5
14.5
9.25
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2.76B
1.76B
1.57B
1.39B
1.38B
1.18B
1B
853.43M
727.07M
619.42M
134.53M
19.82M
-133.01M
76.93M
62.37M
17.84M
15.2M
12.95M
11.03M
9.4M
-33.71M
-36.27M
-27.65M
-23.55M
-23.6M
-19.87M
-16.93M
-14.42M
-12.29M
-10.47M
100.82M
-16.45M
-160.66M
53.38M
38.77M
-2.03M
-1.73M
-1.47M
-1.26M
-1.07M
9.25
9.25
9.25
9.25
9.25
-1.86M
-1.45M
-1.13M
-881.81k
-687.64k
-6.01M
9.25
-1.09M
-15.06M
-9.67M
-15.68M
325.52M
-341.2M
32.56M
-10.48
-10.48 1.182%